Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.

Technology: general issues --- History of engineering & technology --- Materials science --- poly(lactic-co-glycolic acid) (PLGA) --- blood–brain barrier (BBB) --- current Good Manufacturing Practice (cGMP) --- Food and Drug Administration (FDA) --- nanotechnology --- PLGA nanoparticles --- neurodegenerative diseases --- drug delivery --- central nervous system --- neuroprotective drugs --- fluorescent labeling --- DiI --- coumarin 6 --- rhodamine 123 --- Cy5.5 --- quantum yield --- brightness --- stability of fluorescent label --- confocal microscopy --- intracellular internalization --- in vivo neuroimaging --- double-emulsion method --- dry powder inhalation --- antigen release --- porous PLGA particles --- microfluidics --- methotrexate --- chitosan --- PLA/PLGA --- sustained release --- micro-implant --- animal model --- minimally invasive --- drug delivery system --- nanoparticles --- poly (lactic-co-glycolic acid) (PLGA) --- microfluidic --- pharmacokinetics (PK) and biodistribution --- atorvastatin calcium --- poly(lactide-co-glycolide) --- polymeric nanoparticles --- carrageenan induced inflammation --- anti-inflammatory --- radiolabeled nanoparticles --- nuclear medicine --- photothermal therapy --- phthalocyanine --- SKOVip-kat --- Katushka --- TurboFP635 --- JO-4 --- PLGA --- orthotopic tumors --- 3D culture --- spheroids --- poly(lactic-co-glycolic acid) --- nanomedicine --- scale-up manufacturing --- clinical translation --- inline sonication --- tangential flow filtration --- lyophilization --- downstream processing --- H. pylori --- design of experiments --- poly(lactic-co-glycolic) acid --- size --- cancer --- chemoimmunotherapy --- immunogenic cell death --- immune checkpoint blockade --- PNA5 glycopeptide --- mas receptor --- angiotensin --- PLGA diblock copolymer --- ester and acid-end capped --- double emulsion solvent evaporation --- biocompatible --- biodegradable --- cardiovascular --- nanoparticle --- solid-state characterization --- in vitro --- drug release kinetics modeling --- PEGylation --- amine --- emulsion --- polyvinyl alcohol (PVA) --- Pluronic triblock copolymer --- trehalose --- sucrose --- Indomethacin --- solvents --- stabilizers --- morphology --- particle-size --- encapsulation --- drug release --- cytotoxicity --- poly(lactic-co-glycolic acid) (PLGA) --- blood–brain barrier (BBB) --- current Good Manufacturing Practice (cGMP) --- Food and Drug Administration (FDA) --- nanotechnology --- PLGA nanoparticles --- neurodegenerative diseases --- drug delivery --- central nervous system --- neuroprotective drugs --- fluorescent labeling --- DiI --- coumarin 6 --- rhodamine 123 --- Cy5.5 --- quantum yield --- brightness --- stability of fluorescent label --- confocal microscopy --- intracellular internalization --- in vivo neuroimaging --- double-emulsion method --- dry powder inhalation --- antigen release --- porous PLGA particles --- microfluidics --- methotrexate --- chitosan --- PLA/PLGA --- sustained release --- micro-implant --- animal model --- minimally invasive --- drug delivery system --- nanoparticles --- poly (lactic-co-glycolic acid) (PLGA) --- microfluidic --- pharmacokinetics (PK) and biodistribution --- atorvastatin calcium --- poly(lactide-co-glycolide) --- polymeric nanoparticles --- carrageenan induced inflammation --- anti-inflammatory --- radiolabeled nanoparticles --- nuclear medicine --- photothermal therapy --- phthalocyanine --- SKOVip-kat --- Katushka --- TurboFP635 --- JO-4 --- PLGA --- orthotopic tumors --- 3D culture --- spheroids --- poly(lactic-co-glycolic acid) --- nanomedicine --- scale-up manufacturing --- clinical translation --- inline sonication --- tangential flow filtration --- lyophilization --- downstream processing --- H. pylori --- design of experiments --- poly(lactic-co-glycolic) acid --- size --- cancer --- chemoimmunotherapy --- immunogenic cell death --- immune checkpoint blockade --- PNA5 glycopeptide --- mas receptor --- angiotensin --- PLGA diblock copolymer --- ester and acid-end capped --- double emulsion solvent evaporation --- biocompatible --- biodegradable --- cardiovascular --- nanoparticle --- solid-state characterization --- in vitro --- drug release kinetics modeling --- PEGylation --- amine --- emulsion --- polyvinyl alcohol (PVA) --- Pluronic triblock copolymer --- trehalose --- sucrose --- Indomethacin --- solvents --- stabilizers --- morphology --- particle-size --- encapsulation --- drug release --- cytotoxicity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations.

Technology: general issues --- History of engineering & technology --- Materials science --- poly(lactic-co-glycolic acid) (PLGA) --- blood–brain barrier (BBB) --- current Good Manufacturing Practice (cGMP) --- Food and Drug Administration (FDA) --- nanotechnology --- PLGA nanoparticles --- neurodegenerative diseases --- drug delivery --- central nervous system --- neuroprotective drugs --- fluorescent labeling --- DiI --- coumarin 6 --- rhodamine 123 --- Cy5.5 --- quantum yield --- brightness --- stability of fluorescent label --- confocal microscopy --- intracellular internalization --- in vivo neuroimaging --- double-emulsion method --- dry powder inhalation --- antigen release --- porous PLGA particles --- microfluidics --- methotrexate --- chitosan --- PLA/PLGA --- sustained release --- micro-implant --- animal model --- minimally invasive --- drug delivery system --- nanoparticles --- poly (lactic-co-glycolic acid) (PLGA) --- microfluidic --- pharmacokinetics (PK) and biodistribution --- atorvastatin calcium --- poly(lactide-co-glycolide) --- polymeric nanoparticles --- carrageenan induced inflammation --- anti-inflammatory --- radiolabeled nanoparticles --- nuclear medicine --- photothermal therapy --- phthalocyanine --- SKOVip-kat --- Katushka --- TurboFP635 --- JO-4 --- PLGA --- orthotopic tumors --- 3D culture --- spheroids --- poly(lactic-co-glycolic acid) --- nanomedicine --- scale-up manufacturing --- clinical translation --- inline sonication --- tangential flow filtration --- lyophilization --- downstream processing --- H. pylori --- design of experiments --- poly(lactic-co-glycolic) acid --- size --- cancer --- chemoimmunotherapy --- immunogenic cell death --- immune checkpoint blockade --- PNA5 glycopeptide --- mas receptor --- angiotensin --- PLGA diblock copolymer --- ester and acid-end capped --- double emulsion solvent evaporation --- biocompatible --- biodegradable --- cardiovascular --- nanoparticle --- solid-state characterization --- in vitro --- drug release kinetics modeling --- PEGylation --- amine --- emulsion --- polyvinyl alcohol (PVA) --- Pluronic triblock copolymer --- trehalose --- sucrose --- Indomethacin --- solvents --- stabilizers --- morphology --- particle-size --- encapsulation --- drug release --- cytotoxicity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Poly(lactic-co-glycolic acid) (PLGA) is one of the most successful polymers used for producing therapeutic devices, such as drug carriers (DC). PLGA is one of the few polymers that the Food and Drug Administration (FDA) has approved for human administration due to its biocompatibility and biodegradability. In recent years, DC produced with PLGA has gained enormous attention for its versatility in transporting different type of drugs, e.g., hydrophilic or hydrophobic small molecules, or macromolecules with a controlled drug release without modifying the physiochemical properties of the drugs. These drug delivery systems have the possibility/potential to modify their surface properties with functional groups, peptides, or other coatings to improve the interactions with biological materials. Furthermore, they present the possibility to be conjugated with specific target molecules to reach specific tissues or cells. They are also used for different therapeutic applications, such as in vaccinations, cancer treatment, neurological disorder treatment, and as anti-inflammatory agents. This book aims to focus on the recent progress of PLGA as a drug carrier and their new pharmaceutical applications.

PLGA --- nanoscaled drug delivery --- LED --- cancer --- serum stability --- reactive oxygen species --- cellular uptake --- terahertz spectroscopy --- microspheres --- drug delivery --- formulation development --- molecular mobility --- vitamin E --- tocopherol --- PLA --- core-shell nanoparticles --- controlled drug release --- BMP-2 --- PLGA nanoparticles --- Pluronic F68 --- oxaliplatin --- hydrogel --- intra-abdominal anti-adhesion barrier --- colorectal cancer --- experimental design --- fractional factorial design --- O6-methylguanine DNA methyltransferase (MGMT) protein --- glioblastoma multiforme --- smart nanocarriers --- folic acid --- verteporfin --- cisplatin --- SKOV-3 cells --- CHO-K1 cells --- electroporation --- theranostic cargo --- double emulsion approach --- NSAIDs --- polymeric film --- topical drug delivery --- trolamine salicylate --- triamcinolone acetonide --- microcrystal --- PLGA microsphere --- local delivery --- spray-drying technique --- intra-articular injection --- joint retention --- systemic exposure --- gadolinium --- drug release --- polymeric nanocarrier --- sorafenib --- theranostic nanoparticles --- PLGA-PEG --- nanoparticles --- platelet --- activation --- aggregation --- binding --- uptake --- tissue engineering --- Huntington’s disease --- siRNA --- microcarriers --- mesenchymal stromal cells --- drug delivery systems --- microfluidics --- microparticles --- BMP-2-microspheres --- hydrogel system --- 17-βestradiol release --- bone regeneration --- osteoporosis --- poly-lactide-co-glycolide --- polylactic acid --- alginate --- ophthalmic drug delivery --- dexamethasone --- PLGA-NPs --- nanomedicine --- gastrointestinal tract --- paclitaxel --- in vivo imaging --- controlled release --- risperidone --- microcapsules --- oleogels --- electron microscopy --- three-dimensional X-ray imaging --- nano-CT --- biodegradable polymers --- hydroxy-stearic acid --- PLGA nanocapsules --- magnetic resonance imaging --- photoluminescence --- magnetic targeting --- multimodal imaging --- theranostics --- silicon --- microsphere --- n/a --- Huntington's disease